Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
February 22, 2023 08:30 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the UK’s National Institute for Health and Care Excellence (NICE) provided positive final...
Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the Morgan Stanley 20th Annual Global...
Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
May 18, 2022 16:03 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20,...
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 05, 2022 16:07 ET
|
Vir Biotechnology, Inc.
– $1.2 billion of sotrovimab collaboration revenue recognized in the first quarter – – More than $2.5 billion in cash, cash equivalents, investments and collaboration receivables at the end of the...
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022
April 21, 2022 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter...
Vir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference
March 02, 2022 16:02 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, March 02, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in an infectious disease panel discussion at the 42nd Annual...
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022 16:04 ET
|
Vir Biotechnology, Inc.
– Significant progress made increasing global patient access to sotrovimab; approximately 1.7 million doses sold to date – – $917.2 million of sotrovimab collaboration revenue recognized in 2021 – –...
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
February 10, 2022 16:02 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter...
Vir Biotechnology Appoints Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global
February 08, 2022 06:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Johanna Friedl-Naderer as Executive Vice President and Chief...
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
January 13, 2022 09:02 ET
|
Vir Biotechnology, Inc.
– If authorized, would provide the option for intramuscular administration of sotrovimab, in addition to currently authorized intravenous administration – – Submission follows COMET-TAIL Phase 3...